CogState Aktie

CogState EPS

Delisted·15. jun. 2026

Indtjening pr. aktie (EPS) for CogState (CGS.AX) pr. 12. aug. 2026 er 0,06 USD. I foregående år var Indtjening pr. aktie (EPS) 0,03 USD — en ændring på 85,17 % (højere).

EPS

0,06USD

YoY

85,17%

Senest opdateret:

Indtjening pr. aktie (EPS) for CogState er 2026 0,06 USD. Indtjening pr. aktie (EPS) for CogState var 2025 0,03 USD. Det falder dermed med 85,17% højere sammenlignet med året før.
Access this data via the Eulerpool API

CogState Aktieanalyse

Hvad laver CogState? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om CogState aktie

Indtjening pr. aktie (EPS) for CogState er 0,06 USD i 2026.

Indtjening pr. aktie (EPS) for CogState ændrede sig fra 0,03 USD til 0,06 USD, hvilket repræsenterer en ændring på 85,17 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Indtjening pr. aktie (EPS) CogState siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Indtjening pr. aktie måler den del af virksomhedens fortjeneste, der er allokeret til hver udestående aktie, og er en nøglekenntal til vurdering af en virksomheds rentabilitet pr. aktie.

EPS = Nettoindtjening / Udestående aktier

Access this data via the Eulerpool API

Resultatopgørelse — CogState

Alle nøgletal — CogState